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Summary
Effective management of procedural and postoperative pain in neonates is
required to minimize acute physiological and behavioral distress and may
also improve acute and long-term outcomes. Painful stimuli activate nocicep-
tive pathways, from the periphery to the cortex, in neonates and behavioral
responses form the basis for validated pain assessment tools. However, there
is an increasing awareness of the need to not only reduce acute behavioral
responses to pain in neonates, but also to protect the developing nervous sys-
tem from persistent sensitization of pain pathways and potential damaging
effects of altered neural activity on central nervous system development.
Analgesic requirements are influenced by age-related changes in both phar-
macokinetic and pharmacodynamic response, and increasing data are avail-
able to guide safe and effective dosing with opioids and paracetamol.
Regional analgesic techniques provide effective perioperative analgesia, but
higher complication rates in neonates emphasize the importance of monitor-
ing and choice of the most appropriate drug and dose. There have been signif-
icant improvements in the understanding and management of neonatal pain,
but additional research evidence will further reduce the need to extrapolate
data from older age groups. Translation into improved clinical care will
continue to depend on an integrated approach to implementation that
encompasses assessment and titration against individual response, education
and training, and audit and feedback.
Introduction
Effective and safe management of procedural and
postoperative pain is important for children of all ages
for humanitarian reasons and to minimize acute physi-
ological and behavioral distress. In addition, reducing
pain can improve both acute and long-term outcomes
and evidence to guide pediatric clinical practice is
increasing (1,2). However, neonates and infants are at
increased risk of experiencing moderate to severe pain
during hospital care (3,4). Further, specific evidence is
required to guide neonatal practice and reduce the
need to extrapolate data from older age groups, but
implementation of current best practice is also an
ongoing challenge. Guidelines and local practice pro-
tocols are increasingly available, and although vari-
ability in uptake continues to be reported (5),
improvements have also been noted; for example, with
increased use of opioid analgesia for both procedural
and postoperative pain in NICU (6,7) and protocols
for safe administration in the ward setting (8).
Pain mechanisms in the neonatal period
Responses to painful stimuli can be demonstrated in
nociceptive pathways from the periphery to the cortex in
neonates, although the degree and nature of response
change with age. Peripheral pain receptors (nociceptors)
respond to mechanical, thermal and chemical stimuli
following birth, and peripheral sensitization or primary
hyperalgesia (reduced threshold and enhanced response
to previously painful stimuli) develops within areas of
tissue injury (9).
The spinal cord is an important site for the modula-
tion of nociceptive input but is characterized in early
development by a relative excess of excitation and
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delayed development of local and descending inhibition
(10–12). In addition, there are anatomical changes in the
distribution of incoming sensory fibers in early develop-
ment, as A-beta myelinated fibers (that respond to light
touch and are restricted to laminae III-IV of the adult
dorsal horn) extend into superficial laminae I-II and
overlap with A-delta thin myelinated and unmyelinated
C-fibers that respond to noxious stimuli (12). As a
result, neonatal spinal reflex responses are more general-
ized, and the threshold is lower (i.e., a reflex response is
evoked by a less intense stimulus). Stimulus–response
relationships are still evident in human neonates, as nox-
ious heel lance produces a greater reflex withdrawal
response than touch (13). Neonatal tissue injury, such as
repeated heel lance or inflammation, reduces threshold
(i.e., increases sensitivity), but these effects may be mini-
mized by analgesia (14,15).
Pain signals reach the somatosensory cortex in pre-
term and term neonates. Near-infrared spectroscopy
(NIRS) (16,17) and electroencephalogram recordings
(18) demonstrate alterations in cortical activity follow-
ing heel lance for blood sampling. Postnatal age, sleep
state, opioid analgesia, and previous experience can also
influence the pattern, degree, and latency of response
(19–21).
Acute effects and assessment of neonatal pain
Pain produces a range of physiological and behavioral
responses in neonates that can be utilized in clinical
assessment tools to quantify pain severity and evaluate
analgesic efficacy. A range of validated tools are avail-
able for use in different practice settings (1,2,22,23),
with some examples described in Table 1 (24–27).
Additional measures, such as changes in stress hor-
mones and measures of cortical activity, have been uti-
lized in research settings (9). The adverse impact of
inadequate analgesia/anesthesia on acute morbidity
following neonatal surgery has long been recognized
(28,29).
Long-term effects of neonatal pain
Changing levels of neural activity can alter the normal
development of the central nervous system (CNS). As
a result, there is increasing awareness of the need to
not only reduce acute behavioral responses to neona-
tal pain, but also to protect from persistent sensitiza-
tion of pain pathways and potential damaging effects
of excess activity on brain development (9,29,30). For
example, sucrose effectively reduces the acute behav-
ioral response to painful procedures (31) but does not
reduce spinal reflex response or cortical activity (13)
or prevent hyperalgesia (32) and therefore may not
prevent adverse effects of repeated procedures. Com-
parative studies with other analgesics are required.
Neonatal surgery has been associated with alterations
in future pain response. Following neonatal circumci-
sion without analgesia, the behavioral response to
immunization many months later is enhanced (33).
Increased perioperative analgesic requirements were
noted in infants who had also required surgery as neo-
nates (34). More persistent changes in sensory process-
ing were found in children 8–12 years following
neonatal intensive care (35,36), and the degree of change
was more marked in those who also required surgery
during the neonatal period (37).
Studies in postnatal rodents allow evaluation of the
effects of pain and injury at different stages of mamma-
lian development. Age-dependent changes in response
to neonatal injury have been demonstrated, with long-
term alterations in sensory function that are not seen
when the same injury is performed at older ages. Under-
lying mechanisms and modification by analgesia can
also be assessed (9). Altering sensory input into the
spinal cord during the neonatal period impairs normal
development of both excitatory and inhibitory synaptic
function (10,11). Plantar hindpaw incision, an estab-
lished model of postoperative pain demonstrates differ-
ences in the acute and long-term impact of neonatal
surgical injury (38–40). Prior neonatal incision effects
both excitatory and inhibitory synaptic function (41–43)
and increased microglial reactivity in the spinal cord
(44) contributes to an enhanced degree and duration of
hyperalgesia following subsequent injury. Peripheral
nerve block modulates these effects (40,45), and ongoing
studies will allow the evaluation of other analgesic
interventions.
Adverse neurodevelopmental outcomes following
neonatal intensive care are well documented (see Mar-
low, this edition). Increased exposure to procedural pain
has been associated with poorer cognitive and motor
scores (46), impairments of growth (47), reduced white
matter and subcortical gray matter maturation (48), and
altered corticospinal tract structure (49). In addition,
poorer neurodevelopmental outcomes have been
reported in surgical vs nonsurgical groups following pre-
term birth (50) and with surgical vs medical manage-
ment of patent ductus arteriosus (PDA) and necrotizing
enterocolitis (51–53). Patients with significant neonatal
brain injury are often excluded, and statistical methods
are used to correct for potential confounding factors.
Specific contributions of pain, analgesia, and anesthesia
can be difficult to determine, and respiratory disease
(54) and hypotension (48,55) make independent contri-
butions.
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Opioid analgesia
Pharmacokinetics and mechanisms
Intravenous opioid requirements during intensive care
management (56) and the postoperative period (8,57)
are lower in neonates than in infants and children.
Pharmacokinetic parameters are influenced by age
and clinical state, with decreased clearance in neo-
nates, and additional variability following cardiac sur-
gery and with changes in organ function and blood
flow (e.g., reduced hepatic blood flow and morphine
clearance with positive pressure ventilation) (58,59). A
recent model based on bodyweight was able to predict
clearance across all age ranges, including neonates
(60). Laboratory studies also document age- and
dose-dependent changes following systemic (61), epi-
dural (62,63), or intrathecal (64) administration and
allow evaluation of associated pharmacodynamic
changes. Altered opioid receptor distribution and den-
sity in the dorsal root ganglion and spinal cord con-
tribute to increased sensitivity (61,65,66) and are not
solely related to changes in blood–brain barrier per-
meability for morphine (63) as an increased effect for
the same CNS tissue concentration is present at younger
ages (67).
Analgesic efficacy
Intravenous opioid infusions have an established role
for perioperative analgesia in neonates (1). Protocols
vary and include continuous infusions, intermittent
bolus doses, or nurse-controlled analgesia (NCA)
(8,57,68). NCA is delivered via the same type of pump
as patient-controlled analgesia, with a prescribed bolus
and dose interval, but addition of background infusions
in opioid-na€ıve neonates may increase the risk of
respiratory depression (8,68)). Examples of local NCA
protocols can be found at www.gosh.nhs.uk/health-pro
fessionals/clinical-specialties/pain-control-service-inform
ation-for-health-professionals/download-documentation/.
Protocols need to be sufficiently flexible to allow for in-
terindividual variability and titration against individual
response, with regular assessment of pain score, efficacy
and side-effects. Morphine and fentanyl are most often
used. There is limited specific data to guide remifentanil
dosing in neonates (69,70), but use in NICU for analge-
sia and sedation (71), perioperative analgesia (72), and
intubation (73) has been reported, and the short dura-
tion of action may be advantageous for procedural pain
management in NICU (74,75).
Side effects
Fear of side effects, particularly respiratory depression,
has contributed to inadequate use of opioids in neo-
nates. Large audits have demonstrated higher rates of
opioid-induced respiratory depression in neonates than
in older children (2.5% vs 0.27%), but long-term seque-
lae are rare with appropriate monitoring and manage-
ment (8,68). Overall, doses did not differ between
neonates with or without respiratory depression, but
risk was increased by preterm birth and intercurrent
comorbid conditions (8,68).
Opioid withdrawal in neonates is a significant
problem following maternal opioid use during preg-
nancy (neonatal abstinence syndrome) and is also asso-
ciated with significant neurodevelopmental impairment
(76,77). However, iatrogenic opioid tolerance and with-
drawal symptoms also occur in neonates, particularly
with prolonged use, continuous rather than intermittent
administration, and shorter acting agents such as
Table 1 Examples of neonatal pain assessment tools
Tool Parameters Score Utility
Premature infant pain profile
(PIPP) (24)
Gestational age, behavioral state, heart rate, oxygen
saturation, brow bulge, eye squeeze, nasolabial
furrow
Total: 0–21
each parameter scored 0–3; ≤6
minimal pain; >12 moderate to
severe pain
Procedural and
postoperative
pain
FLACC (25) Face, legs, activity, cry, consolability Total: 0–10
each parameter scored 0–2; >4
moderate pain; >7 severe pain
Procedural and
postoperative
pain
COMFORT scale (behavioral
and physiological
parameters) (26)
Alertness, calmness, respiratory distress, movement,
muscle tone, facial tension, blood pressure, heart
rate
Total: 8–40
each parameter scored 1–5; 17–26
adequate sedation; ≥27 inadequate
sedation/analgesia
Pain and
sedation in
NICU
COMFORT behavior scale
(27)
Alertness, calmness, respiratory response (ventilated
neonate) or crying (not ventilated), movement,
muscle tone, facial expression
Total: 8–30
each parameter scored 1–5; >17
moderate pain requiring intervention
Postoperative
pain in NICU
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fentanyl (70,78,79). Assessment tools and management
protocols are available (78,80).
Long-term effects of neonatal opioids
Evaluating the long-term impact of pain and analgesia
in clinical cohorts is dependent on correction for clinical
confounders and will also be influenced by the sensitivity
of the outcome measure and age at follow-up. Following
NICU, greater overall exposure to intravenous mor-
phine was associated with poorer motor development at
8 months, but not at 18 months (46). Associations
between routine use of morphine for sedation during
mechanical ventilation and poor neurodevelopmental
outcome (81) have not been confirmed in all analyses
(55,82,83), and there is often limited data on indication
(e.g., sedation, procedural, or postoperative pain), and
variability in dose and duration of therapy (84). Initial
follow-up of mechanically ventilated neonates at 5 years
of age suggested an impairment on one component
(visual analysis) of the IQ test (85), but subsequent
evaluation of neuropsychological outcomes in the same
population at 8–9 years reported no impairment related
to neonatal morphine use (86).
Associations between exposure to general anesthesia
in early life, increased levels of neuronal apoptosis (pro-
grammed cell death), and impaired neurodevelopmental
outcomes have been demonstrated in a number of mam-
malian species (87–89). Laboratory models have also
evaluated the impact of neonatal opioid exposure on
neuronal apoptosis, but it is important to differentiate
dose schedules associated with the development of
dependence and tolerance (which may be relevant to
prolonged NICU care) from perioperative analgesic
dosing. Subcutaneous morphine 0.3–1.0 mgkg1 pro-
duces analgesia in neonatal rats (61). When tolerance is
induced by subcutaneous morphine 10 mgkg1 bd from
postnatal day P1 to P7 (90), neuronal apoptosis is
increased in the cortex and amygdala, but not in regions
important for memory (hippocampus) or nociceptive
processing (periaqueductal gray, PAG) (91). In adult
rats, repeated intrathecal morphine (0.03 mgkg1 bd
for 7 days) produces tolerance and increases apoptosis
in the spinal cord (92). However, in neonatal rodents,
single doses of morphine up to 3 mgkg1 (300 times the
analgesic dose of 0.01 mgkg1 at this age) did not
increase apoptosis or produce any long-term impair-
ment of spinal function, measured by sensory reflex
thresholds and gait analysis (64). Whereas general anes-
thesia for 4 h with isoflurane, nitrous oxide, and
midazolam increased cortical apoptosis in the neonatal
piglet (93) and guinea pig (94), no significant increase
was seen in sham control groups given fentanyl
(30 mcgkg1 bolus and 4 h infusion 15 mcgkg1h1).
Daily subcutaneous morphine 0.5 mgkg1 from P1 to
P3 or P1 to P5 did not alter levels of apoptosis in the
brain. When combined with a pain stimulus (daily paw
injection of formalin), this analgesic dose of morphine
reduced injury-related apoptosis in the P1–P3 group,
but not in the more prolonged pain group (P1–P5 for-
malin plus morphine) (95). Further studies are required
to evaluate relationships between opioids and injury-
induced apoptosis and investigate other mechanisms
influencing neurodevelopmental outcomes.
Paracetamol
Pharmacokinetics and mechanisms
The pharmacokinetic profile of paracetamol in neonates
has been evaluated following rectal (96), intravenous
(97) and repeat IV doing over 4 days (98), and issues of
neonatal dosing discussed (99). Clearance is related pre-
dominantly to weight (57% of variance), and age
between postmenstrual age 28–44 weeks has minimal
effect (2.2% variance) (97). A 20 mgkg1 loading and
10 mgkg1 IV dose every 6 h was predicted to achieve a
serum concentration of 11 mgL1 in neonates (32–
44 weeks PMA), although it was noted that safety data
for this dose and drug are limited in neonates (97).
Different mechanisms contribute to the analgesic
effect of paracetamol (see recent reviews (100,101)),
including:
1. Prostaglandin-mediated effects, as despite the limited
peripheral anti-inflammatory action compared with
NSAIDs, central effects may relate to interaction
with different cyclo-oxygenase sites (102).
2. The metabolite N-arachydonylphenolamine (AM404)
is a ligand for the cannabinoid CB1 receptor and an
uptake inhibitor of anandamide (an endogenous can-
nabinoid) (103).
3. Interaction with serotonergic mechanisms enhances
inhibitory pathways descending from the brainstem
to the spinal cord (104).
4. Effects on the spinal neurotransmitter nitric oxide.
Dose-dependent analgesic efficacy and specific spinal
cord-mediated effects have been demonstrated in adult
animal models (105,106), but further evaluation of dose
response and mechanisms during postnatal development
is warranted.
Analgesic efficacy
Analgesic efficacy of paracetamol is influenced by dose,
route of administration, and type of pain stimulus. Oral
© 2013 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd.
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paracetamol 20 mgkg1 in neonates did not reduce the
behavioral response to heel prick (107). Intravenous par-
acetamol (20 mgkg1 loading, 5–10 mgkg1 6-h, and
20–40 mgkg1 per 24 h maximum) was effective for
moderate pain in neonates in NICU, producing a signifi-
cant trend to lower pain scores at 30 min, with a slight
decrease in effect by 5–6 h (108). In the perioperative
setting, multimodal analgesia with addition of paraceta-
mol to opioid regimes can reduce opioid requirements
and/or improve analgesia (109). Rectal paracetamol
(30–40 mgkg1 loading and 20 mgkg1 6–8 h) did not
reduce NCA opioid requirements in neonates and
infants following major surgery, although marked vari-
ability in plasma concentration following rectal dosing
was noted (110). A recent study from the same group
noted a significant reduction in opioid requirements in
neonates and infants following major surgery with intra-
venous paracetamol (30 mgkg1 per day in four doses)
(111). Current recommended doses for intravenous
paracetamol in term neonates are 7.5 mgkg1 6-h with
a maximum daily dose of 30 mgkg1 (1) (www.rcoa.ac.
uk/system/files/intravenousparacetamol.pdf). Ongoing
studies and monitoring are required to further evaluate
analgesic dose response and safety in neonates.
Recent case series have reported an association
between use of IV paracetamol 60 mgkg1d1 for
3–6 days and PDA closure in preterm neonates
(112–114). Although significant morbidity may be asso-
ciated with the alternative treatment (indomethacin/ibu-
profen or surgical closure), caution with these high
doses of paracetamol is also warranted, and there is no
confirmed mechanism for this effect of paracetamol that
allows prediction of the appropriate dose (113).
Side effects
In preterm and term neonates undergoing procedures in
NICU, intravenous paracetamol 10 or 20 mgkg1 pro-
duced statistically significant but modest reductions in
heart rate (average 7 bmin1 at 30–120 min) and blood
pressure (3 mmHg at 60 min). Changes were more
marked in neonates with preexisting hypotension, sug-
gesting impaired hemodynamics may be a relative con-
traindication to IV paracetamol (115).
Paracetamol overdose and hepatotoxicity has been
reported in neonates (99,116,117) and infants (118).
Awareness of the risk of accidental administration of
milliliter rather than milligram resulting in a 109 over-
dose, and use of smaller intravenous paracetamol vials
for neonates, has been highlighted by The UK Medi-
cines and Healthcare Products Regulatory Agency
(MHRA; www.mhra.gov.uk/Safetyinformation/Drug-
SafetyUpdate/CON088171).
Mechanisms of paracetamol toxicity are discussed in
recent reviews (99,113). Briefly, oxidative metabolism of
paracetamol (normally 5–10% vs. 50–60% glucuronida-
tion and 25–30% sulfation) results in formation of the
intermediate N-acetyl-p-benzoquinone imine (NAPQI).
Although usually conjugated to glutathione and excreted
in the bile, paracetamol overdose or glutathione lack
results in accumulation of NAPQI and toxicity due to
apoptosis and necrosis of hepatocytes. Although a
reduced rate of oxidation and increased ability to replete
glutathione may be protective for neonates (119), there is
little data on relationships between paracetamol dose and
NAPQI levels, or capacity for NAPQI detoxification in
neonates, and immaturity of hepatic transporters or poor
nutritional statusmay increase susceptibility (99,113).
Long-term effects
An epidemiologic link has been reported between parac-
etamol use in early life and increased risk of asthma in
childhood (120,121). Others have reported that an
increased number of respiratory infections, rather than
paracetamol per se, is the important contributing factor
(122,123). Differentiating association and causation is
also difficult as the proportion of infants and children
who receive paracetamol is high: 51% by 12 weeks of
age and 97% by 2 years in a cohort with a family history
of allergy (123); and over 1% before 8 weeks age and
almost 95% by 4.5 years in a UK cohort (124).
Regional analgesia
Techniques and efficacy
A range of regional analgesic techniques can be effec-
tively used in neonates (see recent reviews plus special
edition of Pediatric Anesthesia January 2012) (125–127).
Although analgesic efficacy has been demonstrated for
many, there has been limited direct comparison of tech-
niques or evaluation of relative benefits and risks in con-
trolled trials in neonates (1). Dorsal penile nerve block
was more effective than topical local anesthetic for
circumcision performed in awake neonates (128). Ilio-
inguinal and rectus sheath blocks are the commonest
intraoperative regional blocks for neonates (129), trans-
versus abdominus plane (TAP) blocks are feasible (130),
and local anesthetic wound infiltration is commonly
performed, but additional larger studies are required to
confirm benefit (131). Additional benefit may be gained
if long-acting local anesthetic preparations are shown to
be effective and safe in neonates (132–134).
Spinal/intrathecal, epidural, and caudal routes are
utilized for neuraxial anesthesia and/or analgesia in
© 2013 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd.
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neonates (127,129,135,136). Potential advantages include
reducing general anesthetic and opioid requirements, and
case series report a reduction in the need for postopera-
tive mechanical ventilation and specific benefit for neo-
nates susceptible to respiratory complications (127,137).
Complications
Large series from the United Kingdom (138), Europe
(129), United States (139), and Canada (140) demon-
strate low complication rates following neuraxial anal-
gesia in children, but rates are higher for central vs
peripheral blocks (129). In early series, neonates were at
greater risk and also had worse outcomes (141,142).
Recent series have also reported higher complication
rates and more pump programming errors in neonates
(129,138,140), thus emphasizing the need for careful
monitoring and follow-up.
Prolonged general anesthesia in neonatal rodents
increases apoptosis in the spinal cord as well as the brain
(143,144). This, plus the lack of systematic data evaluat-
ing spinal analgesic toxicity in early development has
emphasized the need for preclinical evaluation of spinally
administered drugs (127,145,146). No histological injury
or increased apoptosis was found following spinal anes-
thesia with bupivacaine (143) or levobupivacaine (147) in
neonatal rodents. Maximum tolerated doses of intrathe-
cal morphine and clonidine (up to 300 times the analgesic
dose) did not alter spinal cord histology or function
(64,148). By contrast, analgesic doses of intrathecal keta-
mine increased apoptosis and altered long-term sensory
function (149). Although no adverse effects directly
related to caudal additives have been reported, there has
been limited follow-up in clinical trials. As a result of
adverse histological effects in both neonatal and adult
animals following neuraxial delivery (150), clinical use of
caudal ketamine has reduced (136,145,151).
Future directions
Significant advances continue to be made in the under-
standing and management of neonatal pain. Factors
that may contribute to further improvements include:
1. Increased high-quality evidence from neonatal trials
rather than reliance on extrapolation of doses and
techniques from older age groups (1). As ethical and
organizational difficulties make recruitment difficult,
and samples may be small and heterogeneous, multi-
centre trials may be required.
2. Availability of pharmacokinetic and pharmacody-
namic data from clinical and laboratory studies will
continue to inform age- and injury-specific dosing
(59,152).
3. Concerns regarding acute side effects have limited
use of analgesia in the past, but improvements in
monitoring and protocols for safe delivery have sig-
nificantly improved clinical utility.
4. Additional direct comparison of analgesic techniques
in neonates will further delineate the relative safety
and efficacy of different drugs and techniques, partic-
ularly as the developing nervous system responds dif-
ferently to pain, anesthesia, and analgesia, and
potential adverse impacts on neurodevelopmental
outcome may also differ (9).
5. Increased validation and use of neonatal pain assess-
ment tools have improved clinical practice and facili-
tated titration of analgesia against individual
response. However, these tools necessarily rely on
observer assessment of behavioral and/or physiologi-
cal responses as proxy measures of pain and are less
specific and sensitive than assessment at older ages
(23) (4). A range of neurophysiological and hormonal
measures are being evaluated in research studies and
may provide useful comparative data in the future.
Importantly, in addition to the above measures,
improvements in clinical practice are critically depen-
dent on implementation of current best evidence. An
integrated approach is required (153), with targeted edu-
cation and practice interventions, use of validated
assessment tools, local protocols for analgesic adminis-
tration, and regular audit and feedback, to ensure trans-
lation into improved outcomes for neonates requiring
anesthesia, surgery, and intensive care.
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